Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Now, Gilead argues that the “significant and meaningful” improvement in progression-free survival as shown in Ascent-04 “further reinforces the potential of Trodelvy plus Keytruda as a much ...

You can reach Adam on Signal at stataf.54. Gilead Sciences said Monday that a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less ...

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda. ASCENT-04 ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

However, in the ASCENT-04 study, there was an early trend in improvement for OS with Trodelvy plus Keytruda. Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further ...

Gilead said the safety profile of Trodelvy plus Keytruda was consistent with what has been seen when the drugs are used separately. Trodelvy's label carries a boxed warning for neutropenia ...